Skip to main content
Smart Investors Daily
XR

NASDAQ · XRTX

XORTX Therapeutics Inc.

Healthcare · Biotechnology

$1.04

Down-$0.06 (-5.45%)

Updated Nov 17, 2026, 2:38 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.34M
P/E ratio
-1.24
Dividend yield
0.00%
52-week range
$0.82 – $3.60
Volume
943.71K
Avg. volume
1.97M

Price performance · XRTX

XRTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

XRTX closed at $1.04 after 21 trading sessions, up 2.97% for the selected period.

Last close
$1.04
Period change
+2.97%
Period low
$0.85
Period high
$1.10
Daily close
View OHLC price history
XRTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$1.06$1.44$0.8678$1.04943.71K
Nov 13, 2026$0.9097$1.1991$0.8151$1.101.6M
Nov 12, 2026$0.8923$0.93$0.85$0.92641.44K
Nov 11, 2026$0.8497$0.9499$0.8356$0.8936.41K
Nov 10, 2026$0.85$0.9225$0.83$0.8510.34K
Nov 9, 2026$0.9214$0.9428$0.8401$0.84526.5K
Nov 6, 2026$0.90$0.945$0.8603$0.9113.37K
Nov 5, 2026$0.9411$0.9526$0.89$0.9231.6K
Nov 4, 2026$1.01$1.03$0.98$0.9917.94K
Nov 3, 2026$1.065$1.065$1.00$1.005.44K
Nov 2, 2026$1.03$1.06$0.9722$1.0112.51K
Oct 30, 2026$1.01$1.1099$0.945$1.0024.99K
Oct 29, 2026$0.98$1.15$0.952$1.0314.32K
Oct 28, 2026$1.02$1.082$1.02$1.0511.06K
Oct 27, 2026$1.03$1.11$0.915$1.1039.17K
Oct 26, 2026$0.90$1.14$0.83$1.06120.71K
Oct 23, 2026$0.95$0.95$0.915$0.920120.23K
Oct 22, 2026$0.9851$0.9851$0.91$0.968824.72K
Oct 21, 2026$0.9687$1.05$0.9002$0.930172.29K
Oct 20, 2026$0.99$1.04$0.92$0.955587.11K
Oct 19, 2026$1.22$1.24$0.9901$1.01130.1K

Latest XRTX news

The latest Smart Investors Daily articles mentioning XRTX.

XRTX research

Overview

Company profile and research snapshot.

Company profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
XRTX recent ratings
DateFirmRatingTarget
May 8, 2023ALLIANCE GLOBAL PARTNERSBuy—
May 7, 2023ALLIANCE GLOBAL PARTNERSBuy—
Apr 10, 2023ALLIANCE GLOBAL PARTNERSBuy—
Apr 22, 2022Alliance Global PartbersBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Oct 12, 2026

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 million. XORTX Therapeutics (NASDAQ:XRTX) shares moved

Yahoo · Oct 8, 2026

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout

● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide an outline of its anticipated Clinical Trial Application (“CTA”) submiss

Yahoo · Sep 18, 2026

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.